Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible

Executive Summary

New Q&A guidance also states that its near-term focus for resources will be on coronavirus and some other conditions.

You may also be interested in...



Coronavirus Notebook: Emergency Use Authorization For Blood Plasma Therapy, Pandemic Workloads, US FDA Offices, Rx Mail Deliveries

US FDA issues controversial use emergency authorization for blood plasma therapy while agency officials note workloads nearly double under coronavirus treatment acceleration program. This and more in the Pink Sheet's latest coronavirus update.

PDUFA VII Talks To Begin With COVID-19, Other Familiar Issues To Consider

US FDA staffing problems and patient engagement enhancements will be listed as priorities during reauthorization kick-off meeting.

The End Of The FDA Approvals Boom? Fewer Applications Are A COVID-19 Consequence

Applications for US FDA approval are lower than in recent history, portending a lean 2021.

Related Content

Topics

UsernamePublicRestriction

Register

PS142289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel